AIM:To test whether colchicine would be an effective antif ibrotic agent for treatment of chronic liver diseases in patients who could not be treated with α-interferon.METHODS:Seventy-four patients(46 males,28 female...AIM:To test whether colchicine would be an effective antif ibrotic agent for treatment of chronic liver diseases in patients who could not be treated with α-interferon.METHODS:Seventy-four patients(46 males,28 females) aged 40-66 years(mean 53±13 years) participated in the study.The patients were affected by chronic liver diseases with cirrhosis which was proven histologically(n=58);by chronic active hepatitis C(n=4),chronic active hepatitis B(n=2),and chronic persistent hepatitis C(n=6).In the four patients lacking histology,cirrhosis was diagnosed from anamnesis,serum laboratory tests,esophageal varices and ascites.Patients were assigned to colchicine(1 mg/d) or standard treatment as control in a randomized,double-blind trial,and followed for 4.4 years with clinical and laboratory evaluation.RESULTS:Survival at the end of the study was 94.6% in the colchicine group and 78.4% in the control group(P=0.001).Serum N-terminal peptide of type Ⅲ procollagen levels fell from 34.0 to 18.3 ng/mL(P=0.0001),and pseudocholinesterase levels rose from 4.900 to 5.610 mU/mL(P=0.0001) in the colchicine group,while no signif icant change was seen in controls.Best results were obtained in patients with chronic hepatitis C and in alcoholic cirrhotics.CONCLUSION:Colchicine is an effective and safe antifibrotic drug for long-term treatment of chronic liver disease in which fi brosis progresses towards cirrhosis.展开更多
AIM: To assess the impact of procollagen Ⅲ peptide as a marker of collagenesis in the development of pseudopolyps in patients with ulcerative colitis.METHODS: Development of pseudopolyps was monitored in 25 patients ...AIM: To assess the impact of procollagen Ⅲ peptide as a marker of collagenesis in the development of pseudopolyps in patients with ulcerative colitis.METHODS: Development of pseudopolyps was monitored in 25 patients with ulcerative colitis classified according to Powell-Tuck index as mild (n=12) or moderate (n=13) form of disease. Patients with a mild form of disease were treated with oral mesalazine medication (2-4 g/day) and local mesalazine preparation (suppository). Patients with a moderate form of disease received oral mesalazine medication (2-4 g/day), local mesalazine preparation(suppository) and local methylprednisolone at an initial dose of 60 rag/day, followed by dose tapering. How many significant variables (previously determined by analysis of variance) were elevated in the groups with and without pseudopolyp developement was observed. ROC analysis for calculation of new index was made.RESULTS: Serum values of procollagen Ⅲ peptide (PⅢP), C-reactive protein (CRP) and C4 complement component (C4)were statistically significantly lower in the group of patients flee from pseudopolyp development bhan bhose who developed one or more pseudopolyps (0.45±0.12 vs 1.42±0.70,P<0.0027; 7.6±4.7 vs 17.8±9.17, P<0.035, and 0.46±0.11 vs 0.34±0.16, P<0.068, respectively) at endoscopic conrtrols with patohistologically samples during 13 months. There were no statistically significant differences in the values of C3, ceruloplasmin and IgM between the two groups (P>0.05).Discrimination function analysis yielded highest standardized cannon coefficients for PⅢP (0.876), CRP (0.104), C3 (-0.534) and C4 (0.184) (P<0.036). The elevation in two of three laboratory variables (PⅢP, CRP and C4) reached sensitivity of 93 % and specificity of 90 % in the development of pseudopolyps.CONCLUSION: It is proposed that an increase in two of the three laboratory parameters (PⅢP, CRP and C4) could improve the accuracy of prediction of the development of pseudopolyps. When using PⅢP, CRP and C4 on decision making, the positive predictive value and accuracy were 90 % and 92 %, respectively.展开更多
目的:探讨全髋关节置换术的CroweⅢ-Ⅳ型发育性髋关节发育不良(developmental dysplasia of the hip,DDH)患者的满意度及造成不满意的相关因素。方法:回顾性分析2013年3月至2018年3月行全髋关节置换术的169例CroweⅢ-Ⅳ型DDH患者,通过...目的:探讨全髋关节置换术的CroweⅢ-Ⅳ型发育性髋关节发育不良(developmental dysplasia of the hip,DDH)患者的满意度及造成不满意的相关因素。方法:回顾性分析2013年3月至2018年3月行全髋关节置换术的169例CroweⅢ-Ⅳ型DDH患者,通过微信进行调查问卷,调查患者对手术总体满意度、10项日常功能满意度和患者认为对自己日常生活影响比较大的前5个问题。手术前后采用髋关节Harris评分进行功能评价。结果:收到完整调查问卷145份,所有患者获随访,时间1~5(3.23±1.22)年。145例患者分成两组,其中对手术疗效满意的118例,不满意的27例,手术总体满意率81.38%(118/145)。患者认为对生活影响比较大的前5个问题分别是术后髋部疼痛,肢体明显不等长、行走、上下楼梯、蹲起。两组术前Harris评分比较,差异无统计学意义(P>0.05),不满意组术后Harris评分较低。术后髋关节疼痛、肢体不等长是影响手术不满意的直接因素。结论:采用全髋关节置换术治疗CroweⅢ-Ⅳ型DDH患者手术难度大;术后髋关节疼痛(轻度以上),肢体不等长(>2 cm)是术后不满意的独立危险因素。展开更多
目的:检测慢性心力衰竭(CHF)患者血清Ⅲ型前胶原氨基末端前肽(N-terminal peptide of typeⅢprocollagen,PⅢNP)、高迁移率族蛋白B1(high mobility group box-1,HMGB1)的表达水平,探讨二者与左室射血分数(LVEF)的相关性以及对CHF的诊断...目的:检测慢性心力衰竭(CHF)患者血清Ⅲ型前胶原氨基末端前肽(N-terminal peptide of typeⅢprocollagen,PⅢNP)、高迁移率族蛋白B1(high mobility group box-1,HMGB1)的表达水平,探讨二者与左室射血分数(LVEF)的相关性以及对CHF的诊断价值。方法:收集2021年12月至2022年11月期间于佳木斯大学附属第一医院心内科住院治疗的慢性心力衰竭患者90例为实验组,按照LVEF将其分为HFrEF组(n=33)、HFmrEF组(n=27)和HFpEF组(n=30)。此外选取排除心功能不全诊断的同期住院患者30例为对照组。对比各组患者血清中氨基末端脑钠肽前体(NT-proBNP)、PⅢNP、HMGB1水平的差异,分析PⅢNP、HMGB1水平与心功能指标的相关性,并借助ROC曲线评估NT-proBNP、HMGB1、PⅢNP单独以及联合应用对不同表型CHF患者的诊断价值。结果:HFrEF组PⅢNP、HMGB1及NT-proBNP水平均高于HFpEF组和对照组,差异有统计学意义(P<0.05)。PⅢNP与HMGB1呈正相关(P<0.05);PⅢNP、HMGB1均与NT-proBNP、LVEDD呈正相关,与LVEF呈明显负相关(P<0.05);HMGB1与LAD呈正相关(P<0.05),PⅢNP与LAD无明显相关性(P>0.05)。血清NT-proBNP、HMGB1、PⅢNP水平诊断HFrEF患者的AUC分别为0.867、0.871、0.779;诊断HFmrEF患者的AUC分别为0.840、0.804、0.760;诊断HFpEF患者的AUC分别为0.851、0.728、0.769。多生物标志物模型NT-proBNP+PⅢNP、NT-proBNP+HMGB1、NT-proBNP+PⅢNP+HMGB1诊断HFrEF患者的AUC分别为0.887、0.954、0.954;诊断HFmrEF患者的AUC分别为0.942、0.937、0.951;诊断HFpEF患者的AUC分别为0.904、0.910、0.914。结论:CHF患者血清PⅢNP、HMGB1明显升高,并且,CHF患者血清PⅢNP、HMGB1水平与心脏功能指标具有良好的相关性,说明PⅢNP、HMGB1可反映疾病的严重程度。PⅢNP、HMGB1对各表型CHF患者均具有诊断价值,并且,多生物标志物联合检测能提高对CHF患者诊断的敏感性。展开更多
文摘AIM:To test whether colchicine would be an effective antif ibrotic agent for treatment of chronic liver diseases in patients who could not be treated with α-interferon.METHODS:Seventy-four patients(46 males,28 females) aged 40-66 years(mean 53±13 years) participated in the study.The patients were affected by chronic liver diseases with cirrhosis which was proven histologically(n=58);by chronic active hepatitis C(n=4),chronic active hepatitis B(n=2),and chronic persistent hepatitis C(n=6).In the four patients lacking histology,cirrhosis was diagnosed from anamnesis,serum laboratory tests,esophageal varices and ascites.Patients were assigned to colchicine(1 mg/d) or standard treatment as control in a randomized,double-blind trial,and followed for 4.4 years with clinical and laboratory evaluation.RESULTS:Survival at the end of the study was 94.6% in the colchicine group and 78.4% in the control group(P=0.001).Serum N-terminal peptide of type Ⅲ procollagen levels fell from 34.0 to 18.3 ng/mL(P=0.0001),and pseudocholinesterase levels rose from 4.900 to 5.610 mU/mL(P=0.0001) in the colchicine group,while no signif icant change was seen in controls.Best results were obtained in patients with chronic hepatitis C and in alcoholic cirrhotics.CONCLUSION:Colchicine is an effective and safe antifibrotic drug for long-term treatment of chronic liver disease in which fi brosis progresses towards cirrhosis.
文摘AIM: To assess the impact of procollagen Ⅲ peptide as a marker of collagenesis in the development of pseudopolyps in patients with ulcerative colitis.METHODS: Development of pseudopolyps was monitored in 25 patients with ulcerative colitis classified according to Powell-Tuck index as mild (n=12) or moderate (n=13) form of disease. Patients with a mild form of disease were treated with oral mesalazine medication (2-4 g/day) and local mesalazine preparation (suppository). Patients with a moderate form of disease received oral mesalazine medication (2-4 g/day), local mesalazine preparation(suppository) and local methylprednisolone at an initial dose of 60 rag/day, followed by dose tapering. How many significant variables (previously determined by analysis of variance) were elevated in the groups with and without pseudopolyp developement was observed. ROC analysis for calculation of new index was made.RESULTS: Serum values of procollagen Ⅲ peptide (PⅢP), C-reactive protein (CRP) and C4 complement component (C4)were statistically significantly lower in the group of patients flee from pseudopolyp development bhan bhose who developed one or more pseudopolyps (0.45±0.12 vs 1.42±0.70,P<0.0027; 7.6±4.7 vs 17.8±9.17, P<0.035, and 0.46±0.11 vs 0.34±0.16, P<0.068, respectively) at endoscopic conrtrols with patohistologically samples during 13 months. There were no statistically significant differences in the values of C3, ceruloplasmin and IgM between the two groups (P>0.05).Discrimination function analysis yielded highest standardized cannon coefficients for PⅢP (0.876), CRP (0.104), C3 (-0.534) and C4 (0.184) (P<0.036). The elevation in two of three laboratory variables (PⅢP, CRP and C4) reached sensitivity of 93 % and specificity of 90 % in the development of pseudopolyps.CONCLUSION: It is proposed that an increase in two of the three laboratory parameters (PⅢP, CRP and C4) could improve the accuracy of prediction of the development of pseudopolyps. When using PⅢP, CRP and C4 on decision making, the positive predictive value and accuracy were 90 % and 92 %, respectively.
文摘目的:探讨全髋关节置换术的CroweⅢ-Ⅳ型发育性髋关节发育不良(developmental dysplasia of the hip,DDH)患者的满意度及造成不满意的相关因素。方法:回顾性分析2013年3月至2018年3月行全髋关节置换术的169例CroweⅢ-Ⅳ型DDH患者,通过微信进行调查问卷,调查患者对手术总体满意度、10项日常功能满意度和患者认为对自己日常生活影响比较大的前5个问题。手术前后采用髋关节Harris评分进行功能评价。结果:收到完整调查问卷145份,所有患者获随访,时间1~5(3.23±1.22)年。145例患者分成两组,其中对手术疗效满意的118例,不满意的27例,手术总体满意率81.38%(118/145)。患者认为对生活影响比较大的前5个问题分别是术后髋部疼痛,肢体明显不等长、行走、上下楼梯、蹲起。两组术前Harris评分比较,差异无统计学意义(P>0.05),不满意组术后Harris评分较低。术后髋关节疼痛、肢体不等长是影响手术不满意的直接因素。结论:采用全髋关节置换术治疗CroweⅢ-Ⅳ型DDH患者手术难度大;术后髋关节疼痛(轻度以上),肢体不等长(>2 cm)是术后不满意的独立危险因素。
文摘目的:检测慢性心力衰竭(CHF)患者血清Ⅲ型前胶原氨基末端前肽(N-terminal peptide of typeⅢprocollagen,PⅢNP)、高迁移率族蛋白B1(high mobility group box-1,HMGB1)的表达水平,探讨二者与左室射血分数(LVEF)的相关性以及对CHF的诊断价值。方法:收集2021年12月至2022年11月期间于佳木斯大学附属第一医院心内科住院治疗的慢性心力衰竭患者90例为实验组,按照LVEF将其分为HFrEF组(n=33)、HFmrEF组(n=27)和HFpEF组(n=30)。此外选取排除心功能不全诊断的同期住院患者30例为对照组。对比各组患者血清中氨基末端脑钠肽前体(NT-proBNP)、PⅢNP、HMGB1水平的差异,分析PⅢNP、HMGB1水平与心功能指标的相关性,并借助ROC曲线评估NT-proBNP、HMGB1、PⅢNP单独以及联合应用对不同表型CHF患者的诊断价值。结果:HFrEF组PⅢNP、HMGB1及NT-proBNP水平均高于HFpEF组和对照组,差异有统计学意义(P<0.05)。PⅢNP与HMGB1呈正相关(P<0.05);PⅢNP、HMGB1均与NT-proBNP、LVEDD呈正相关,与LVEF呈明显负相关(P<0.05);HMGB1与LAD呈正相关(P<0.05),PⅢNP与LAD无明显相关性(P>0.05)。血清NT-proBNP、HMGB1、PⅢNP水平诊断HFrEF患者的AUC分别为0.867、0.871、0.779;诊断HFmrEF患者的AUC分别为0.840、0.804、0.760;诊断HFpEF患者的AUC分别为0.851、0.728、0.769。多生物标志物模型NT-proBNP+PⅢNP、NT-proBNP+HMGB1、NT-proBNP+PⅢNP+HMGB1诊断HFrEF患者的AUC分别为0.887、0.954、0.954;诊断HFmrEF患者的AUC分别为0.942、0.937、0.951;诊断HFpEF患者的AUC分别为0.904、0.910、0.914。结论:CHF患者血清PⅢNP、HMGB1明显升高,并且,CHF患者血清PⅢNP、HMGB1水平与心脏功能指标具有良好的相关性,说明PⅢNP、HMGB1可反映疾病的严重程度。PⅢNP、HMGB1对各表型CHF患者均具有诊断价值,并且,多生物标志物联合检测能提高对CHF患者诊断的敏感性。